Hematology

Blood disease treatments including therapies for hemophilia, sickle cell disease, and myelodysplastic syndromes.

Companies

Pipeline Drugs

365

Key People

506

Hematology Pipeline (365 drugs)

Approved: 109Commercial: 43Phase 3: 39Phase 1: 28Phase 2: 22Phase 1/2: 21Preclinical: 18Pre-clinical: 16Pending Approval: 12Approved/Commercial: 6Phase 2/3: 5Multiple: 4Discovery/Preclinical: 4Research: 3Clinical: 3Preclinical/Phase 1: 3Phase 1b: 3IND-Enabling: 2Undisclosed: 2Phase 3-ready: 2Service: 2Late-stage: 1NDA Submitted: 1Development: 1Phase 1 to Commercial: 1Pre-clinical to Filing: 1Clinical Development: 1Submitted: 1Phase 1 / Phase 2: 1Emergency Use Authorization: 1Preclinical/Discovery: 1NDA/BLA Filed: 1Research/Development: 1Phase 2b: 1Phase 1/2a: 1Clinical-stage: 1Pre-clinical/Discovery: 1Platform/Service: 1Service/Diagnostic: 1

Drug	Company	Indication	Phase	Status
Opdivo (nivolumab)	Bristol Myers Squibb	Multiple cancer types	Commercial	Approved
Yervoy (ipilimumab)	Bristol Myers Squibb	Melanoma and other cancers	Commercial	Approved
Revlimid (lenalidomide)	Bristol Myers Squibb	Multiple myeloma	Commercial	Approved
Eliquis (apixaban)	Bristol Myers Squibb	Atrial fibrillation	Commercial	Approved
Sprycel (dasatinib)	Bristol Myers Squibb	CML, ALL	Commercial	Approved
Breyanzi (lisocabtagene)	Bristol Myers Squibb	B-cell lymphomas	Commercial	Approved
Abecma (idecabtagene)	Bristol Myers Squibb	Multiple myeloma	Commercial	Approved
Camzyos (mavacamten)	Bristol Myers Squibb	Hypertrophic cardiomyopathy	Commercial	Approved
Zeposia (ozanimod)	Bristol Myers Squibb	Multiple sclerosis	Commercial	Approved
Reblozyl (luspatercept)	Bristol Myers Squibb	Anemia disorders	Commercial	Approved
Camrelizumab (SHR-1210)	Jiangsu Hengrui Medicine	Multiple cancer types	Approved	Commercial
Pyrotinib	Jiangsu Hengrui Medicine	HER2-positive breast cancer	Approved	Commercial
Fluzoparib	Jiangsu Hengrui Medicine	BRCA-positive ovarian cancer	Approved	Commercial
SHR-1316	Jiangsu Hengrui Medicine	Solid tumors	Phase 1/2	Active
SHR-1701	Jiangsu Hengrui Medicine	Advanced solid tumors	Phase 1	Active
SHR-1905	Jiangsu Hengrui Medicine	Hematologic malignancies	Phase 1	Active
Sevoflurane	Jiangsu Hengrui Medicine	General anesthesia	Approved	Commercial
Ropivacaine	Jiangsu Hengrui Medicine	Local anesthesia	Approved	Commercial
Iohexol	Jiangsu Hengrui Medicine	Contrast imaging	Approved	Commercial
Hemlibra (emicizumab)	Chugai Pharmaceutical	Hemophilia A	Approved	Commercial
Tecentriq (atezolizumab)	Chugai Pharmaceutical	Multiple Cancers	Approved	Commercial
Kadcyla (T-DM1)	Chugai Pharmaceutical	HER2+ Breast Cancer	Approved	Commercial
Phesgo	Chugai Pharmaceutical	HER2+ Breast Cancer	Approved	Commercial
Herceptin (trastuzumab)	Chugai Pharmaceutical	HER2+ Cancers	Approved	Commercial
Avastin (bevacizumab)	Chugai Pharmaceutical	Multiple Cancers	Approved	Commercial
Actemra (tocilizumab)	Chugai Pharmaceutical	Rheumatoid Arthritis	Approved	Commercial
Satralizumab	Chugai Pharmaceutical	Neuromyelitis Optica	Approved	Commercial
Crovalimab	Chugai Pharmaceutical	Paroxysmal Nocturnal Hemoglobinuria	Phase 3	Active
GYM329	Chugai Pharmaceutical	Spinal Muscular Atrophy	Phase 2	Active
Tiragolumab	Chugai Pharmaceutical	Cancer combination therapy	Phase 3	Active
CSL112	CSL	Acute Coronary Syndrome	Phase 3	Active
CSL312	CSL	Hereditary Angioedema	Phase 3	Active
Eteplirsen	CSL	Duchenne Muscular Dystrophy	Commercial	Marketed
Hemgenix (CSL222)	CSL	Hemophilia B	Commercial	FDA Approved
CSL200	CSL	Wilson Disease	Phase 1/2	Active
Albumin Products	CSL	Multiple Critical Care Indications	Commercial	Marketed
Immunoglobulin Therapies	CSL	Primary Immunodeficiencies	Commercial	Marketed
Factor VIII Products	CSL	Hemophilia A	Commercial	Marketed
Xarelto (rivaroxaban)	Bayer	Anticoagulation	Approved	Commercial
Eylea (aflibercept)	Bayer	Wet AMD, Diabetic Macular Edema	Approved	Commercial
Nexavar (sorafenib)	Bayer	Hepatocellular carcinoma, Renal cell carcinoma	Approved	Commercial
Stivarga (regorafenib)	Bayer	Colorectal cancer, GIST	Approved	Commercial
Vitrakvi (larotrectinib)	Bayer	TRK fusion cancers	Approved	Commercial
Nubeqa (darolutamide)	Bayer	Prostate cancer	Approved	Commercial
Kerendia (finerenone)	Bayer	Diabetic kidney disease	Approved	Commercial
BAY 1817080	Bayer	Multiple solid tumors	Phase 1	Active
BAY 1895344	Bayer	Advanced solid tumors	Phase 1	Active
BAY 2927088	Bayer	Solid tumors	Phase 1	Active
BRUKINSA (zanubrutinib)	BeOne Medicines	B-cell malignancies, CLL/SLL	Approved	Commercial
TEVIMBRA (tislelizumab)	BeOne Medicines	Various solid tumors	Approved	Commercial